Related Experiment Video
Updated: Jul 13, 2026
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
RB activity alters checkpoint response and chemosensitivity in lung cancer lines
Michael F Reed1, William A Zagorski, Erik S Knudsen
1Division of Thoracic Surgery, Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267-0558, USA. michael.reed@uc.edu
Background:
The retinoblastoma tumor suppressor (RB) is a key regulator of cell cycle progression and is functionally inactivated in the majority of human non-small cell lung cancers (NSCLC). The specific influence of RB on therapeutic response in NSCLC remains elusive.
Materials And Methods:
We investigated the consequence of reintroduction of RB on checkpoint response and chemosensitivity in NSCLC cell lines. RB introduction into RB-proficient (NCI-H1299) and -deficient (H1734, H2172) NSCLC cells was achieved by adenoviral infection. RB/E2F target gene expression was determined by immunoblot analysis. Cell cycle response and viability after chemotherapeutic exposure were assessed by flow cytometry and MTT viability assay.
Results:
RB reconstitution in RB-deficient lines restored regulation of topoIIalpha, thymidylate synthase, and cyclin A. Similarly, RB overexpression in RB-proficient cells caused further regulation of some RB/E2F target genes including thymidylate synthase and topoIIalpha. In addition, RB overexpression resulted in restoration of the G1 arrest mechanism. Exposure of RB-proficient cells to cisplatin, etoposide, or 5-fluorouracil elicited arrest in various phases of the cell cycle while lines deficient for RB exhibited different checkpoint responses. However, introduction of RB restored ability to arrest following chemotherapeutic exposure. Chemotherapeutic challenge resulted in varying effects on cellular viability independent of RB status, yet restoration of RB activity conferred partial chemoresistance.
Conclusions:
These results demonstrate that RB reconstitution into RB-deficient NSCLC lines establishes regulation of certain RB/E2F target genes and restores G1 arrest mechanisms. Furthermore, introduction of RB enhances the G1 checkpoint response to chemotherapeutics and decreases chemosensitivity. Knowledge of RB-dependent chemosensitivity may ultimately contribute to individualized therapy based on molecular characterization of tumors.
Insights
Restoring the retinoblastoma tumor suppressor (RB) in non-small cell lung cancer (NSCLC) cells re-established cell cycle control and G1 arrest. This RB reconstitution partially enhanced chemoresistance, suggesting a role in individualized NSCLC therapy.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- The retinoblastoma tumor suppressor (RB) is crucial for cell cycle regulation.
- RB is frequently inactivated in non-small cell lung cancer (NSCLC).
- The impact of RB on NSCLC treatment response is not well understood.
Purpose of the Study:
- To investigate the effects of RB reintroduction on cell cycle checkpoint response in NSCLC.
- To determine how RB influences chemosensitivity in NSCLC cell lines.
Main Methods:
- Adenoviral vectors were used to introduce RB into RB-proficient and RB-deficient NSCLC cell lines.
- RB/E2F target gene expression was analyzed.
- Cell cycle progression and viability were assessed after chemotherapy exposure using flow cytometry and MTT assays.
Main Results:
- RB reconstitution restored regulation of key genes like thymidylate synthase and topoIIalpha in RB-deficient cells.
- RB overexpression re-established the G1 cell cycle arrest mechanism.
- Introduction of RB enhanced the G1 checkpoint response to chemotherapeutics and conferred partial chemoresistance.
Conclusions:
- RB reintroduction in NSCLC cells restores cell cycle control and G1 arrest.
- RB status influences checkpoint response and chemosensitivity to common chemotherapeutics.
- Understanding RB's role may enable personalized NSCLC treatment strategies.
